| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| ln Vitro |
For a duration of 24 hours, oxLDL (20 μg/mL) and Nagilactone B (0.02, 0.1, and 0.5 μM) were treated with RAW264.7 cells. Following oxLDL treatment, RAW264.7 cells exhibited a considerable lipid buildup and foam cell development, as demonstrated by Oil Red O (ORO) staining. Nucleotide-binding protein B (NLB) dramatically enhances intracellular lipid accumulation. The Nagilactone B (0.02, 0.1, and 0.5 μM) treatment group showed a reduction in the ORO-positive region of 30.05±7.49 (P<0.01), 47.25±5.39 (P<0.001), and 48.65±7.44% (P<0.001). correspondingly. Large cholesterol efflux was used to gauge Nagilactone B's impact. The study found that nagilactone B (0.02, 0.1, and 0.5 μM) significantly increased the efflux of cholesterol to high-density lipoprotein (HDL) and extracellular apolipoprotein AI (apoA-I), by up to 5.72-fold (P<0.05) and 2.34-fold (P<0.05), respectively, with P<0.01[1].
|
|---|---|
| ln Vivo |
By causing ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1)-mediated cholesterol efflux in macrophages, nagilactone B (NLB) prevents atherosclerosis in apoE-/-mice. For a duration of 12 weeks, male C57BL/6J mice defective in apoE were administered a dose of 10 and 30 mg/kg of Nagilactone B. When compared to the model group, nagilactone B treatment (10 and 30 mg/kg) dramatically decreased frontal lesions in the entire aortic area. For a period of 12 weeks, six-week-old male apoE-/-HFD mice were randomly assigned to receive CMC-Na, naginolactone B (10 and 30 mg/kg/day), or atorvastatin (10 mg/kg/day). CMC-Na-fed mice served as the control group's regular diet. ORO staining was used to track the lesion area in the aortic sinus, whereas Sudan IV staining was used to evaluate the frontal aortic lesion region. While aortic surface lesions grew dramatically in the HFD model group, atherosclerosis progressed slowly in the normal diet group. Frontal aortic lesions were considerably reduced by nagilactone B treatment (10 and 30 mg/kg/day), with reductions of 54.96±10.06% (P<0.01) and 71.50±15.37% (P <0.001). NLB (H) group as well. Specifically, aortic arch, thoracic aorta, and abdominal aorta atherosclerotic plaque lesion regions were dramatically decreased by Nagilactone B [NLB (H) group P<0.01][1].
|
| References | |
| Additional Infomation |
Nagilactone B has been reported in Afrocarpus gracilior, Podocarpus macrophyllus, and Nageia nagi with data available.
|
| Molecular Formula |
C19H24O7
|
|---|---|
| Molecular Weight |
364.3897
|
| Exact Mass |
364.152
|
| CAS # |
19891-51-1
|
| PubChem CID |
3084329
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
644.6±55.0 °C at 760 mmHg
|
| Melting Point |
258-261℃
|
| Flash Point |
233.7±25.0 °C
|
| Vapour Pressure |
0.0±4.3 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
-0.18
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
766
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(C)C1=C2[C@H]([C@@H]3[C@H]4[C@](C[C@H]([C@H]([C@@]4(C2=CC(=O)O1)C)O)O)(C(=O)O3)C)O
|
| InChi Key |
AEGWYWSJGKOLGB-ZLNDBNLZSA-N
|
| InChi Code |
InChI=1S/C19H24O7/c1-7(2)13-11-8(5-10(21)25-13)19(4)15-14(12(11)22)26-17(24)18(15,3)6-9(20)16(19)23/h5,7,9,12,14-16,20,22-23H,6H2,1-4H3/t9-,12-,14-,15+,16-,18+,19-/m1/s1
|
| Chemical Name |
(1S,8R,9S,12S,14R,15S,16R)-8,14,15-trihydroxy-1,12-dimethyl-6-propan-2-yl-5,10-dioxatetracyclo[7.6.1.02,7.012,16]hexadeca-2,6-diene-4,11-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7443 mL | 13.7216 mL | 27.4431 mL | |
| 5 mM | 0.5489 mL | 2.7443 mL | 5.4886 mL | |
| 10 mM | 0.2744 mL | 1.3722 mL | 2.7443 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
